1	
2	
3	
4	
5	
6	
7	FULL TITLE
8	Virtual Assessment of Patients with Dry Eye Disease During the COVID-19 Pandemic: One clinician's
9	experience
10	
11	SHORT TITLE
12	Virtual Dry Eye Consultations During COVID-19
13	
14	AUTHORS
15	Pierre Ibrahim ¹ , Caroline G. McKenna ² , Rookaya Mather ³
16	
17	¹ Western University, London, ON, Canada
18	² BScH, Schulich School of Medicine and Dentistry, London, ON, Canada
19	³ MD, FRCSC, Schulich School of Medicine and Dentistry, Department of Ophthalmology, London, ON, Canada
20	
21	Keywords: Dry Eye Disease, COVID, virtual care, quality of life, patient adherence
22	
23	Corresponding Author:
24	Caroline McKenna
25	cmckenna2023@meds.uwo.ca
26	1151 Richmond Street, London, Ontario, N6A 5C1
27	Schulich School of Medicine, Western University
28	Tel: 905-699-8307

29 ABSTRACT:

30 **Objectives:** To report on 1) the impact of DED on social, mental, and financial well-being, and 2) the use of virtual

31 consultations to assess DED during the COVID-19 pandemic.

32 Design & Methods: An exploratory retrospective review of 35 charts. Telephone consultations for patients with

33 DED conducted during the first lock-down period in Ontario in 2020 were reviewed.

34 **Results:** The most commonly reported DED symptoms were ocular dryness, visual disturbances, and burning

35 sensation. The most common dry eye management practices were artificial tears, warm compresses, and omega-3

36 supplements. 20.0% of charts documented worsening of DED symptoms since the onset of the pandemic and 17.1%

37 reported the lockdown had negatively affected their ability to perform DED management practices. 42.8% of

patients reported an inability to enjoy their daily activities due to DED symptoms. 52.0% reported feeling either

depressed, anxious, or both with 26.9% of patients accepting a referral to a social worker for counselling support.

40 More than a quarter of the charts recorded financial challenges associated with the cost of therapy, and more than a

41 fifth of patients reported that financial challenges were a direct barrier to accessing therapy.

42 Conclusions: Patients living with DED reported that their symptoms negatively affected their daily activities

43 including mental health and financial challenges, that in turn impacted treatment practices. These challenges may

44 have been exacerbated during the COVID-19 pandemic. Telephone consultations may be an effective modality to

45 assess DED symptom severity, the impact of symptoms on daily functioning, and the need for counselling and

46 support.

47

48 AUTHOR SUMMARY:

49 Dry Eye Disease occurs when your tears do not provide enough lubrication for your eyes, which can be caused by 50 either decreased tear production, or by poor quality tears. This study reviewed 35 patient charts to examine 1) the 51 impact of Dry Eye Disease on patients' well-being, and 2) the use of telephone appointments to assess Dry Eye 52 Disease during the COVID-19 pandemic. Patients reported an inability to enjoy their daily activities due to 53 symptoms of dry eye including burning sensation and blurred vision. Over half of patients reported mental health 54 challenges. Over a quarter of patients reported that financial challenges prevented them from treating their Dry Eve 55 Disease, such as affording eye drops, dietary supplements, and appointments to see their optometrist. These findings 56 highlight that healthcare providers should considering quality of life, mental health, and financial challenges when

57 treating patients with Dry Eye Disease. Through the experience of an ophthalmologist who specializes in Dry Eye

58 Disease, telephone appointments may be an effective way to assess Dry Eye Disease symptoms, the impact of

59 symptoms on daily functioning, and the need for counselling and support.

60

61 **INTRODUCTION:**

62 Dry eye disease (DED) is a multifactorial disease of the ocular surface characterized by loss of homeostasis of the

tear film. Tear film instability and hyperosmolarity leads to ocular surface inflammation and damage(1), resulting in

64 symptoms including burning and gritty sensation, photophobia, foreign body sensation, excess tearing, visual

disturbances, and difficulty performing visual tasks(2). DED is a chronic and incurable disease, affecting an

66 estimated six million Canadian adults(3). DED is known to negatively affect quality of life, work productivity(4),

67 sleep(5), emotional well-being(2,6,7), and other everyday activities(8). Moreover, the negative impact of DED on

68 daily living has been associated with mental health challenges such as depression and anxiety(9).

69

70 The COVID-19 pandemic has affected access to healthcare in Canada with devastating effects on healthcare systems

71 globally. Canada's pre-existing health care system was challenged with lengthy wait times(10) prior to the

72 pandemic. Long wait times have been further exacerbated by the COVID-19 pandemic when lockdown periods

resulted in cancelled or postponed appointments and delays in delivering care. In 2020, national wait times were

74 longest for referral to ophthalmology compared to any other specialist referral with an average wait of 34.1

75 weeks(11).

76

Since the onset of the COVID-19 pandemic, many physicians have turned to virtual appointments as a solution in which physicians meet with patients via telemedicine modalities including phone and video chat. In Canada, virtual health care visits with primary care physicians and specialists jumped from 4% to 60% at the onset of the COVID-19 pandemic(10). There is existing literature presenting the use of virtual care for ophthalmic conditions such as glaucoma(12,13). During the Ontario COVID-19 lockdown period starting March 2020, non-urgent patient visits to the clinic were cancelled.

83

- 84 The objectives of this study are as follows: To report on 1) the impact of DED on patients' social, mental, and
- 85 financial well-being during the COVID-19 pandemic and 2) the experience of using virtual consultations to assess
- 86 patients with DED during the COVID-19 pandemic.
- 87

88 MATERIAL AND METHODS:

89 <u>Study Design</u>:

Retrospective chart-review study from one cornea specialist practice at the Ivey Eye Institute, Schulich School of
 Medicine, Western University, London, Ontario, Canada. Patients had been referred by their optometrist or
 ophthalmologist for evaluation of dry eye disease. Only patients with adequate visual acuity (VA > 20/30) and
 normal intraocular pressure (IOP < 22mmHg), as documented by referring eyecare providers, were selected for

- 94 virtual consultations.
- 95

96 Consultations were provided virtually over the phone using a structured questionnaire based on questions routinely
97 asked in-person, and using validated questionnaires that are typically self-administered by patients during in-person
98 consultations. The virtual consultation was divided into two parts; the first part was administered by a clinical
99 assistant to obtain medical and ocular histories, document symptoms, current treatment, and CDEA (Canadian Dry
100 Eye Assessment) and DEQ-5 (Dry Eye Questionnaire-5) scores in the same way that an ophthalmic technician
101 would gather this information in a clinic setting. The second part of the DED consultation was conducted by
102 telephone with the cornea specialist.

103

In light of the many disruptions to daily routines during the lockdown period, such as increased screen time from working from home, patients were asked whether their DED symptoms had changed during the lockdown and whether the lockdown was affecting their ability to engage in DED self-care. Clinical information was extracted from the charts and documented into data collection sheet with responses to 39 questions (S1 Appendix).

109 <u>Patient Population:</u>

All patients were referred by a physician or optometrist with an established diagnosis of DED. Patients were
 selected for virtual care appointments based on normal intraocular pressure and visual acuity, as reported by the

referring physician or optometrist or ophthalmologist. A total of 35 patients had a virtual appointment booked. Six patients attended only the first part of the consultation. The data from first part of the consultation were included in the chart review.

115

116 Data Analysis:

Results are presented as a percentage of total responses collected for each question, as well as mean values of total responses. DED Management score (DEDM) is a composite score created to capture overall DED management practices using five indicators: use of artificial tears, use of tear gel, use of omega-3 supplements, use of warm compresses to the eyes, and use of eyelid cleansing. DEDM scores were tabulated by adding one point for each of the practices, leading to a scale from 0 to 5, where 5 indicates using all five management practices and 0 indicates using none the management practices. Spearman's Rho tests were used to compare percentage values. JASP (v0.14.1) was used to conduct statistical analysis and results were considered statistically significant if P<0.05.</p>

124

125 **RESULTS**:

126 Participant Demographics:

127 All charts (n= 35) recorded age, sex, general health history, including previously diagnosed Sjörgren's syndrome, 128 co-morbidities and systemic medications. All charts also documented ocular health history, dry eye history, ocular 129 topical medications and other DED treatments, and frequency of optometric care. A total 35 patients completed the 130 first part of the consultation interview with the clinical assistant. While not all patients answered every question, all 131 completed questions were analyzed in the chart review as a proportion of those that did answer the question. On 132 average, patients reported experiencing DED symptoms for 6.14 years prior to ophthalmology consultation and 133 visiting their optometrist 1.61 times per year regarding DED (Table 1). A fifth of charts documented patients with a 134 pre-existing diagnosis of Sjögren's syndrome. 78.13% of charts documented a DEQ-5 score equal to or greater than 135 12, suggesting Sjögren's related DED and warranting further work-up. 21.21% of charts documented severe DED 136 symptoms and 48.48% had moderate DED symptoms according to CDEA scores equal to or greater than 31. 137

Table 1: Participant Demographics	Ν	% or Mean	
Total participants	35		
Years living with DED symptoms (mean)		6.14 years	

Visits to doctor for DED complaints yearly	35	
Mean		1.61 +/-1.37
More than once per year	14	40.00%
Previous Sjögren's diagnosis	35	
Yes	7	20%
No	28	80%
Dry Eye Questionnaire (DEQ-5) Score	32	
Mean		13.875
Sjogren's (DEQ- $5 > 12$)	25	78.13%
Canadian Dry Eye Assessment (CDEA) Score	33	
Mean		23.700
Mild (CDEA 5-20)	10	30.30%
Moderate (CDEA 21-30)	16	48.48%
Severe (CDEA 31-48)	7	21.21%

138

139 DED symptoms and management practices:

140 The three most bothersome DED symptoms were documented for each patient. Results are shown in Fig 1. The

141 worst symptoms experienced were ocular dryness (37.14%), blurred/fluctuating vision (20.00%), and

burning/stinging (14.29%).

- 143
- 144 The most common management practices among patients were artificial tear use (82.86%), warm compresses

145 (71.43%), and omega-3 supplements (42.86%) (Table 2). However, among artificial tear users, 52.17% of charts

documented the reported use to be less than three times per day. Among omega-3 users, 30.77% of charts

- documented taking less than the recommended daily dose of 2000 mg.
- 148

Table 2: DED Management Practices	Ν	% or Mean
Artificial tears	35	82.86%
Tear gel or ointment	35	34.29%
Eyelid cleansing daily	35	31.43%
Warm compresses	35	71.43%
Omega-3 supplements	35	42.86%
Mean amount taken per day (mg)		2215.71mg +/- 1001.41
% of patients taking omega-3 who take less than the		30.77%
recommended daily dose (< 2000mg)		
Most common usage frequency of artificial tears (per day)	29	
3 times	7	24.14%
2 times	5	17.24%
Occasional	4	13.79%
Most common brands of artificial tears used	29	
Systane	16	55.17%
Refresh	5	17.24%
Other	5	17.24%
Most common brands of ointment or gel used	11	
Systane	5	45.46%
Ocunox	2	18.18%

	Other	2	18.18%
149			

150 Spearman's Rho analysis revealed that there was no significant correlation between DEDM scores and DEQ-5

151 scores (Table 3). However, there were significant correlations between number of artificial tears used per day and

152 DEQ-5 score (P=0.009), between number of artificial tears per day and DEDM scores (P<0.001), and between

153 number of artificial tears used per day and number of visits to eyecare provider per year (P=0.008).

154

Table 3: Spearman's Rho Analysis						
Variables	CDEA Score	DEQ-5 Score	DEDM Score	Number Of Visits Per Year	Years with Symptoms	Number of Artificial Tears Per Day
CDEA Score	-	-	-	-	-	-
DEQ-5 Score	Rho=0.527	-	-	-	-	-
	<i>p</i> =0.002*					
DEDM Score	Rho=0.192	Rho=0.320	-	-	-	-
	<i>p</i> =0.285	<i>p</i> =0.070				
Number of Visits Per Year	Rho= 0.176	Rho = 0.122	Rho = 0.221	-	-	-
	<i>p</i> =0.327	<i>p</i> =0.499	<i>p</i> =0.217	-		
Years with Symptoms	Rho = 0.245	Rho = 0.350	Rho= 0.173	Rho = -0.076	-	-
	<i>p</i> =0.170	<i>p</i> =0.046	<i>p</i> = 0.335	<i>p</i> =0.673	-	-
Number of Artificial Tears Per Day	Rho = 0.183	Rho= 0.449	Rho = 0.704	Rho= 0.453	Rho= 0.110	-
	<i>p</i> = 0.309	<i>p</i> =0.009*	<i>p</i> =<0.001*	<i>p</i> =0.008*	<i>p</i> =0.542	-

155 * indicates P<0.05

156

157 Impact of DED on daily activities, mental health, and finances:

42.80% of charts documented patients reporting an inability to enjoy their daily activities due to DED symptoms

(Table 4). The top three activities impacted by DED were reading (30.43%), spending time at the computer or

160 watching TV (26.08%), and driving (17.39%) (Fig 2). As part of routine DED consultations, patients were screened

161 for mental health challenges and asked to comment on the severity of their challenges as well whether they wished

- to be referred to social work team at the hospital for additional support. 48.00% of charts reviewed indicated no
- 163 mental health difficulties. 52.00% of participants reported feeling either depressed, anxious, or both and 26.92% had
- accepted a referral to speak with a social worker when offered. More than a quarter of the charts documented
- 165 patients reporting financial challenges associated with their DED. Similarly, more than a fifth of patients revealed
- that financial challenges were a barrier to accessing DED therapy.
- 167

Table 4: Effect of DED on mental, emotional, and financial well-being	Ν	% or Mean
Do your dry eye symptoms limit your ability to perform daily activities?	35	
Yes	15	42.86%
No	20	57.14%
Emotional hardship caused by dry eye (on scale of 1 to 5)	27	
1	16	59.26%
3	6	22.22%
2	4	14.81%
Feelings of depression or anxiety due to dry eye	25	
Depressed	6	24.00%
Anxious	4	16.00%
Both depressed and anxious	3	12.00%
Neither depressed or anxious	12	48.00%
Accepted referred to social worker for depression and/or anxiety	26	
Yes	7	26.92%
No	19	73.08%
Financial challenge of DED (on a scale of 1-5)	26	
1	19	73.08%
3	5	19.23%
4	2	7.69%
Cost of DED therapy as a deterrent of therapy	26	
Yes	6	23.08%
No	20	76.92%

168

169 Impact of COVID-19 lockdown on DED:

170 One fifth of charts documented worse DED symptoms during the lockdown period compared to prior to the

171 lockdown period (Table 5). 17.14% of patients reported the lockdown negatively affected their ability to perform

their DED self-care routine, 2.00% reported their self-care routine was better during the lockdown, and the

- 173 remaining indicated no change.
- 174

Table 5: Impact COVID-19 on DED	Ν	%
Effect of COVID on DED symptoms	35	
Negative effect	7	20.0%
Positive effect	1	2.86%
No effect	27	77.14%
Effect of COVID on DED self-care routine	35	
Negative effect	6	17.14%

No effect	29	82.86%
Effect of COVID on time spent on computer or other screen	34	
More time spent	15	44.12%
Less time spent	19	55.88%

175

176 **DISCUSSION:**

177 In this study, telephone consultations provided clinically useful information, allowing the cornea specialist to assess

and grade patients' current DED symptoms, impact on activities of daily living and mental health, and success in

- engaging in DED self-care activities. In addition, the virtual format allowed patients to disclose challenges requiring
- additional support to cope with DED. Virtual consultations identified patients warranting further investigations for

181 Sjogren's disease. In terms of treatment, telephone consultations allowed for initiation of optimal DED management,

and allowed for triaging patients for subsequent in-person assessment.

183

184 <u>DED symptoms and self-care</u>:

185 In this preliminary chart review, patients were referred to a cornea specialist after an average of 6 years of DED

symptoms, and almost three quarters of patients had moderate or severe DED symptoms according to CDEA scores.

187 The majority of patients reported using artificial tears and warm compresses, and less than half reported using

188 omega-3 supplements. Among those who used artificial tears, many were using drops less than four times per day

despite the severity of symptoms reported. Among those who took omega-3 supplements, approximately one third

190 were taking less than the 2000 mg recommended daily dose. With the information obtained, patients were

counselled regarding optimal DED self-management and educated regarding optimal follow-up and future treatmentmodalities.

193

194 The DEDM score is a novel parameter created to capture overall DED management practices employed by patients.
195 This measure allows researchers to understand how many of the five main practices were employed, to get a sense
196 of self-management in totality. The composite score is a novel way to assess the relationships between patient
197 treatment behaviours/practices and disease severity.

198

A significant correlation was identified between the frequency of artificial tear use and DEQ-5 scores. This was
 expected as worse symptoms intuitively warrant more tear use per day. In addition, the frequency of artificial tear

201	use was correlated with overall DED management composite scores. Perhaps respondents who use tears more often
202	are also more diligent about other elements of their DED self-care, or have the financial means to engage in more
203	elements of self-care. The frequency of artificial tear use correlated with the number of eyecare visits per year,
204	suggesting that more severe DED symptoms may lead to greater healthcare seeking behaviour. Financial means
205	and/or insurance coverage allow patients to afford the cost of both artificial tears and additional eye care
206	appointments. Moreover, seeing an optometrist more frequently may increase the likelihood of adherence to therapy.
207	
208	DED and financial barriers to therapy:
209	Financial barriers associated with therapy may lead to poor adherence to DED self-care. Nearly a quarter of patients
210	reported that the cost of dry eye therapy was a deterrent to therapy adherence. This is consistent with other studies
211	that reported the cost of DED therapy represented an average annual out of pocket expense of \$1,089 CAD per
212	year(14) and \$678-\$1,267 USD per year(15). Moreover, this study found patients to be underutilizing artificial tears
213	and omega-3 supplements. Financial barriers promote rationing of artificial tears and other therapeutics, as reported
214	by Michaelov et al. (14). In addition, financial struggles are likely underreported by patients to eye care providers as
215	previous studies have shown that non-adherence to therapy due to financial reasons is often not disclosed by patients
216	to their health care providers(14). Furthermore, the COVID-19 pandemic has resulted in financial stressors for a
217	large proportion of the population, as reported in a study that found 40% of US adults experienced COVID-19-
218	related financial stressors from March to August 2020(16).
219	
220	In this study population, patients visited their optometrist an average of 1.61 times per year. Interestingly, there was
221	no correlation between frequency of visits and symptom severity. For some patients, insurance coverage may limit
222	visits to once per year. The lack of private insurance coverage may also be a financial barrier to care. Literature
223	demonstrates that lack of government-insured optometric services was found to negatively impact patients' access to
224	health care services, and ultimately vision health outcomes(17). However, these would be an important relationships
225	to evaluate in a larger study sample.
226	

227 <u>DED and mental health</u>:

In this study, over half of patients reported either anxiety, depression, or both, as a result of DED symptoms. This
may be directly associated with symptoms of dry eye, or associated with difficulty performing daily activities due to
DED symptoms. This is consistent with literature demonstrating the association between DED and mental health
issues including anxiety and depression(6,18).

232

233 Over a quarter of patients accepted a referral to a social worker for support regarding living with DED. These

findings highlight the importance of inquiring about mental health during DED appointments and may inform the

rationale behind incorporating mental health screening into the standard of care for DED. This is essential given the

high prevalence of mental health concerns among DED patients(4,7). Optometrists and ophthalmologists should not

only prioritize inquiring about mental health, but also ensure they have the appropriate resources to provide to

238 patients, such as a referral to a social worker, other mental health services, or to primary care providers.

239

Moreover, poor mental health may be exacerbated by the COVID-19 pandemic. There was a marked increase in the number of Canadians reporting 'poor or fair' mental health between March and May 2020, over half of which reported the decline in mental health was directly associated with lockdown measures that resulted in social isolation(19). In addition, the Canadian Mental Health Association reported Canadians were more likely to believe their mental health had worsened compared to physical health during the pandemic(20). While this study was not designed to evaluate an association or temporality between mental health, DED, and COVID-19, we acknowledge the possibility that there may be interactions between these variables.

247

248 DED symptoms and the COVID-19 pandemic:

One fifth of patients reported the pandemic made their DED symptoms worse, and 17% reported it negatively affected their ability to perform their DED self-care. Only 2% reported their symptoms improved. Nearly half of patients reported spending more time using screens, which may be contributing to the worsening symptoms.

Many non-essential medical visits and procedures were postponed due to provincial public health directives. In many cases, this resulted in a negative impact on health outcomes. Through virtual consultations, the patients in this study were assessed and counselled with respect to optimizing their DED self-care management. Despite the lack of

256 physical exam findings such as VA, IOP, and SLE, virtual appointments may serve as a valuable way to initiate 257 management until in-person visits are possible. Moreover, telephone appointments constitute a form of virtual care 258 that doesn't involve apps or video chat, making the modality user-friendly for both clinicians and patients. This 259 achieves a similar goal as in person appointments when specialists provide counseling to patients and advice to 260 referring providers. 261 262 Other forms of virtual care have been employed in ophthalmology. For example, in glaucoma virtual care, patients 263 have been given handheld tonometers to measure IOP remotely to supplement video chat appointments(21). Others 264 are using specialized video chat equipment to allow for improved visualization of the eye during virtual 265 appointments. Recommendations for virtual care within the Canadian healthcare system include introducing 266 education on telemedicine for medical students, and training in telemedicine for physicians with regards to delivery 267 of virtual care, performing virtual patient examinations, and incorporating virtual care into their existing medical 268 practices(22). 269 270 Limitations: 271 This study had a limited sample size due to the study objectives: to provide preliminary exploratory data to examine 272 patient experience with DED during the COVID-19 pandemic, and report on the use of telephone consultations for 273 DED referrals. Further studies are needed to better understand the effect of the COVID-19 pandemic on DED 274 patients, as well as to evaluate the use of telephone, or other virtual care modalities, for DED consultations. 275 Secondly, there are limitations to the composite scoring used in data analysis to capture how many elements of self-276 care patients were engaging in. The composite score weighed each self-care practice equally and without regard for 277 variation, for example using one drop of artificial tears per day versus four times per day. In addition, not all 278 therapies, or frequencies of therapies, are necessarily equally effective. 279 280 Finally, there are limitations to the virtual care modality itself. There were communication challenges over the 281 telephone with some patients. This was especially evident in elderly patients, patients who were hard of hearing, and 282 patients with language barriers. With regards to ophthalmological considerations, physical exam parameters such as

283 VA, IOP, and SLE are impossible to conduct virtually. Though the most recently documented VA and IOP values

- were obtained from optometrist and ophthalmologist referral letters, the lack of contemporaneous VA, IOP, and
- 285 SLEs may represent a limitation to care.
- 286

287 CONCLUSIONS:

- 288 Telephone consultations for patients with DED may be an effective way to assess dry eye disease symptom severity,
- the impact of symptoms on daily functioning, and the need for counselling and support. In this chart review,
- 290 patients living with DED reported symptoms that negatively affected their daily activities including mental health
- and financial challenges, which in turn impact their ability to perform dry eye management activities. These
- challenges may have been exacerbated during the COVID-19 pandemic lockdown. Despite challenges and
- 293 limitations, it is evident that simple virtual care via telephone will continue to play an integral role in DED care in
- the future.
- 295
- **296 S1 APPENDIX.** Virtual Dry Eye Consultation during the COVID-19 Pandemic.
- 297 *History of the Presenting Complaint*
- What are the 3 most troubling eye symptoms you are experiencing? (List most troubling symptom, second most troubling symptom, third most troubling symptom from the list below)
 a. Dryness
 b. Grittiness/Sandiness
- 302 Burning/stinging c. 303 d. Foreign body sensation 304 Photophobia/light sensitivity e. 305 f. Contact lens intolerance 306 Redness g. 307 Mucous discharge h. 308 i. Tearing/watering 309 j. Itching 310 k. Blurred/fluctuating vision 311 1. Other 312 2. How long have you had dry eye symptoms (years)?
 - 313 3. How many times per year do you visit your eye doctor regarding your dry eye?
 - 4. Do you experience blurred vision along with symptoms of dryness?
 - 315 5. Have you been diagnosed with a condition called Sjogren's Syndrome?
 - **316** 6. Do you feel that your mouth is excessively dry?
 - 317 Past Ocular Therapy
 - 318 7. Do you use eye drops for your dry eye condition?
 - 319 8. How often do you use your drops per day?
 - 320 9. What brand of drops do you use?
 - 321 a. Refresh
 - 322 b. Systane

222		T · · ·
323		c. Liposic
324		d. Hydrasense
325		e. Hylo
326		f. Soothe
327	10	g. Other
328		Do you use tear gel or ointments?
329		How often do you use tear gel or ointments per day?
330	12.	What brand of tear gel or ointment do you use?
331		a. Refresh/Lacrilube
332		b. Ocunox
333		c. Systane
334		d. Liposic
335		e. Teargel
336		f. Other
337		Do you perform eyelid cleansing daily?
338		Do you use warm compresses on your eyelids?
339		Do you take omega-3 supplements daily?
340		How much omega-3 do you take daily (mg)?
341		Have you had a chance to read the Dry Eye information package we mailed out to you?
342		DEQ-5 score (/22)?
343		CDEA score (/48)?
344		How many hours per day do you use a computer or other electronic device?
345	21.	Do you use a C-PAP machine?
346	Impact of	of DED Symptoms on Activities
347	22.	Does your dry eye condition limit your ability to perform your daily activities?
348		List the top 3 activities you feel less able to enjoy or do because of your dry eye symptoms.
349		a. Driving
350		b. Spending time at the computer
351		c. Work-related activities such as missing work
352		d. Social activities
353		e. Watching TV
354		f. Going out in public like grocery shopping or to the mall
355		g. Outdoor activities such as walking, biking, playing soccer
356		h. Sleeping
357		i. Other
358	24.	Please rate how financial challenges MAY affect your ability to take care of your eye condition on a scale
359		from 1 to 5 $\{1 = no issues at all; 3 = I find artificial tears and supplements expensive but I do buy what I$
360		need; 4 = I find treatment expensive and can only afford some of what I need 5 = I cannot afford the
361		treatment all}
362	25.	Does the cost of dry eye therapy prevent or limit how well you are able to care for your eyes?
363	26.	Please tell me about the effect Dry Eye has on your mental and emotional well-being $\{1 = no \text{ effect and } 5 = 1\}$
364		severe effect}
365	27.	Do you feel depressed and/or anxious due to your dry eye symptoms?
366	28.	Would you like to talk to someone about how you are feeling? I can refer you to our social worker who has
367		helped many people who are struggling to cope with their dry eye condition?
368	29.	Do you feel the COVID-19 pandemic and shutdown period has had an effect on your Dry Eye symptoms?
369		Better? Worse? No change?
370		a. If worse, why?
371	30.	Did you spend more time using an electronic device?
372		Did the COVID pandemic/lockdown affect your ability to perform your regular Dry Eye self-care routine?
373		If yes, how?


- 374 32. Has COVID pandemic affected how well you are coping with your dry eye condition? Better? Worse? No change?
- a. If worse, in what way?

377 Past Ocular History

- 378 33. Do you have any other eye conditions such as glaucoma or macular degeneration?
- 379 34. Have you had any eye surgery in the past including laser vision correction?
- 380 35. What medical conditions do you have?
- 381 36. What prescription medications do you take?
- **382** 37. Do you have any medication allergies?
- 383 38. Would you like us to email you additional information?
- 384 39. Do you smoke cigarettes?

385


FIGURES:




387 Fig 1a. DED symptoms rated as most bothersome.

388 389

Fig 1b. DED symptoms rated as second most bothersome.










Fig 2a. Most commonly affected activities due to DED.







401 Fig 2b. Second most affected activities due to DED symptoms.





403 404





406 407

408

409 **STATEMENTS**:

410 <u>Competing Interests</u>: All authors certify that they have no affiliations with or involvement in any organization or

- entity with any financial interest or non-financial interest in the subject matter or materials discussed in thismanuscript.
- 413 <u>Funding</u>: No funding was received to assist with the preparation of this manuscript.
- 414 <u>Ethical Standards</u>: The manuscript does not contain clinical studies or patient data.

415 <u>Author Contributions:</u> Conceptualization: Rookaya Mather; Methodology: Rookaya Mather; Formal analysis and

416 investigation: Caroline McKenna, Pierre Ibrahim,; Writing - original draft preparation: Caroline McKenna, Pierre

417 Ibrahim; Writing - review and editing: Rookaya Mather, Caroline McKenna, Pierre Ibrahim; Funding acquisition:

- 418 N/A; Resources: Rookaya Mather; Supervision: Rookaya Mather
- 419

420 **REFERENCES:**

- Craig JP, Nichols KK, Akpek EK, Caffery B, Dua HS, Joo CK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276–83.
- 423 2. Johnson ME. The association between symptoms of discomfort and signs in dry eye. Ocul Surf. 2009;7(4):199–211.
- 425 3. Caffery B, Srinivasan S, Reaume CJ, Fischer A, Cappadocia D, Siffel C, et al. Prevalence of dry eye disease
 426 in Ontario, Canada: A population-based survey. Ocul Surf. 2019;17(3):526–31.
- 4. Sivakumar G, Patel J, Ng G, Mather R, Malvankar M. Impact of dry eye disease on work performance and productivity: A systematic review and meta-analysis. In Quebec City: 2019 COS Annual Meeting; 2019.
 429 Available from: https://www.cos-sco.ca/quebec2019/wp-content/uploads/2019/05/Poster_Booklet2019.pdf

- 430 5. Au N, Mather R, To A, Malvankar-Mehta M. Sleep outcomes associated with dry eye disease: a systematic review and meta-analysis. Can J Opthalmology. 2019;54(2):180–9.
- 432 6. Miljanović B, Dana R, Sullivan DA, Schaumberg DA. Impact of Dry Eye Syndrome on Vision-Related
 433 Quality of Life. Am J Ophthalmol. 2007;143(3):409–15.
- 434 7. Mertzanis P, Abetz L, Rajagopalan K, Espindle D, Chalmers R, Snyder C, et al. The relative burden of dry
 435 eye in patients' lives: Comparisons to a U.S. normative sample. Investig Ophthalmol Vis Sci.
 436 2005;46(1):46–50.
- 8. Saldanha I, Bunya V, McCoy S, Makara M, Baer A, Akpek E. Ocular Manifestations and Burden Related To Sjögren's Syndrome: Results of a Patient Survey [published online ahead of print, 2020 Jun 19]. Am J Ophthalmol.
- 440 9. McDonald M, Patel D, Keith M, Snedecor S. Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review. Ocul Surf. 2016;14(2):144–67.
- Canada Health Infoway. Canadians' Health Care Experiences During COVID-19 [Internet]. 2020. Available
 from: https://www.infoway-inforoute.ca/en/component/edocman/resources/reports/benefits-evaluation/3828 canadians-health-care-experiences-during-covid-19
- Barua B, Moir M. Waiting Your Turn: Wait Times for Health Care in Canada, 2020 Report [Internet]. 2020.
 Available from: https://www.fraserinstitute.org/sites/default/files/waiting-your-turn-2020.pdf
- 447 12. Saleem SM, Pasquale LR, Sidoti PA, Tsai JC. Virtual Ophthalmology: Telemedicine in a COVID-19 Era. Am J Ophthalmol. 2020;216:237–42.
- Bowe T, Hunter D, Mantagos I, Kazlas M, Jastrzembski B, Gaier E, et al. Virtual Visits in Ophthalmology:
 Timely Advice for Implementation During the COVID-19 Public Health Crisis. Telemed J E Heal.
 2020;26(9):1113–7.
- 452 14. Michaelov E, Mather R. Sjögren's Syndrome Associated Dry Eye: Patient Experience and Adherence to
 453 Therapy. In: Canadian Ophthalmological Society Meeting. Quebec City;
- 454 15. Yu J, Asche C V., Fairchild CJ. The economic burden of dry eye disease in the United States: A decision tree analysis. Cornea. 2011;30(4):379–87.
- Ettman C, Abdalla S, Cohen G, Sampson L, Vivier P, Galea S. Low assets and financial stressors associated with higher depression during COVID-19 in a nationally representative sample of US adults. J Epidemiol Community Heal. 2020;
- 459 17. Jin YP, Wedge R, El-Defrawy S, Flanagan JG, Buys YM, Trope GE. Lack of government-funded
 460 optometric services is associated with reduced utilization of eye care providers and increased utilization of
 461 family doctors. In Toronto: CAHSPR Conference; 2014. Available from:
 462 https://pdfs.semanticscholar.org/1c8d/ef976cfaa7bcf6a482bb1c234411166a94ef.pdf
- 463 18. McDonald M, Patel DA, Keith MS, Snedecor SJ. Economic and Humanistic Burden of Dry Eye Disease in Europe, North America, and Asia: A Systematic Literature Review. Ocul Surf. 2016;14(2).
- 465 19. Statistics Canada. Mental Health of Canadians During the COVID-19 Pandemic. May 2020 and March and
 466 April 2020. [Internet]. 2020. Available from: https://www150.statcan.gc.ca/n1/pub/11-627-m/11-627467 m2020039-eng.pdf
- Canadian Mental Health Association. New data shows majority of Ontarians believe mental health crisis
 will follow COVID-19 impact [Internet]. 2020 [cited 2021 Apr 14]. Available from: https://ontario.cmha.ca/news/new-datashows-majority-of-ontarians-believe-mental-health-crisis-will-follow-covid-19-impact/
- Phu J, Masselos K, Kalloniatis M. Deployment of the Water Drinking Test and iCare HOME Phasing for Intraocular Pressure Profiling in Glaucoma Evaluation. Optom Vis Sci. 2021;98(11):1321–31.

474	22.	Kalavar M, Hua H-U, Sridhar J. Teleophthalmology: an essential tool in the era of the novel coronavirus
475		2019. Curr Opin Ophthalmol. 2020;31(5):366–73.